Article: Cytoclonal Pharmaceutics Announces New Business Strategy And Name Change to eXegenics.

- Company Adopts New 'Platform' Business Model -

NEW YORK, Oct. 24 /PRNewswire/ --

The new leadership team of Cytoclonal Pharmaceutics Inc. (Nasdaq: CYPH) today unveiled a new business strategy to move the Company towards a commercially viable, "platform" biotechnology company that can drive revenue-generating partnerships with its drug discovery technologies in the near term, and build an internal drug development pipeline to create longer-term value.

The company also announced a name change to eXegenics Inc. to reflect the new direction of the company. The name change will become official, and trading under the new Nasdaq symbol "EXEG" will ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!